Latest Shareholder Value News

Lykos Metals Limited narrows its Sockovac project tenement while securing an extended exploration permit for Jezero, positioning itself for focused growth in Bosnia and Herzegovina.

Jervois Global Limited has initiated a prepackaged Chapter 11 recapitalisation process in the US, leading to the suspension of its shares on multiple exchanges. Shareholders are being notified with detailed documentation as the company seeks to restructure its finances.

Arrow Minerals has secured $7 million through a well-supported placement to advance its flagship Niagara Bauxite and Simandou North Iron projects in Guinea, setting the stage for key resource milestones and development studies.

Close the Loop Limited has ended acquisition discussions with Adamantem Capital but remains confident in its standalone growth strategy, projecting steady revenue and an EBITDA range of $11m-$13m for the first half of 2025.

Red Hill Minerals reports a robust December quarter with $2.7 million in royalty revenue, a special dividend payout, and promising drilling results across multiple gold and base metal projects.

Infinity Lithium reports steady progress on its San José Lithium Project with updated mining licence requirements and a strategic pivot to new European funding opportunities.

Waratah Minerals has reported significant progress in its Spur Gold-Copper Project, extending gold zones with over 4,700 metres drilled in the December quarter. Strategic board appointments signal a new phase for the company as it positions itself for further exploration success.

Nelson Resources bolstered its balance sheet with a $2.3 million placement and appointed Dr Louis Bucci as Executive Director, setting the stage for renewed exploration at its Fortnum and Yarri gold projects in early 2025.

Algorae Pharmaceuticals reports robust progress in its drug development pipeline, highlighted by promising preclinical results for cardiovascular and dementia candidates and significant AI platform enhancements.

Litchfield Minerals has confirmed a substantial expansion of the Oonagalabi base metal system, extending its geochemical footprint beyond 3km. The company is gearing up for an aggressive 2025 exploration campaign, including geophysical surveys and drilling, despite potential weather-related delays.

Syntara Limited has reported encouraging interim Phase 2 trial results for its lead drug candidate SNT-5505 in myelofibrosis, alongside a successful A$15 million capital raise to advance multiple clinical programs.

Imugene Limited has secured A$20 million through convertible notes as part of a broader A$46 million capital raise, aiming to advance its promising immuno-oncology pipeline.